17 Biotechnology Stocks with More Than 50% Upside

8. Vaxcyte Incorporated (NASDAQ:PCVX)

Number of Hedge Fund Holders: 46

Upside Potential: 115.7%

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside.

On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year. OPUS-2 has already begun participant dosages, and OPUS-3 is set to start in Q1 of 2026. Both studies are expected to deliver results in the first half of 2027.

On January 7, Needham analyst Joseph Stringer raised the price target for Vaxcyte Incorporated (NASDAQ:PCVX) from $90 to $110 and maintained a Buy rating on the stock. This results in more than 100% upside at the prevailing level.

Stringer’s rating is backed by the inclusion of the stock on the firm’s Conviction List, highlighting it as a Top Pick for 2026 after replacing Phathom Pharmaceuticals (PHAT). The analyst shared his view that the strongly positive Phase 2 data for VAX-31 reduce risk ahead of the Phase 3 readout, which is expected in the fourth quarter of 2026. He believes the company’s pneumococcal vaccine retains best-in-class potential.

Vaxcyte Incorporated (NASDAQ:PCVX) is a company developing next-generation vaccines to protect against serious bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.